Skip to main content
SpringerLink
Log in

Behandlung älterer Patienten mit Clozapin

  • Conference paper
Leponex

  • 35 Accesses

Zusammenfassung

Clozapin ist wegen seiner besonderen pharmakologischen Eigenschaften für Patienten, die auf konventionelle Neuroleptika nicht respondieren oder deren Nebenwirkungen nicht tolerieren, eine sinnvolle Alternative. Dies gilt auch für gerontopsychiatrische Patienten. Therapierefraktäre paranoide Syndrome und psychotische Entgleisungen bei M. Parkinson sowie Versuche der Tre-morreduktion stellen Indikationen dar, in denen Clozapin auch bei alten Patienten eingesetzt wird. Bei Durchsicht der Literatur zeigt sich jedoch ein großer Mangel an gesicherten empirischen Daten zur Wirksamkeit und Sicherheit von Clozapin bei Patienten dieser Altersgruppe. Aufgrund der Datenlage kann aber davon ausgegangen werden, daß man mit Clozapin auch bei alten Menschen in unterschiedlichen Indikationsbereichen gute Behandlungserfolge erzielen kann. Die Behandlung alter Patienten mit Clozapin erfordert jedoch besondere Umsicht und Kenntnis der pharmakodynamischen und pharmakokinetischen Besonderheiten im Alter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Almeida OP, Howard RJ, Levy R, David AS (1995) Psychotic states arising in late-life (late paraphrenia); the role of risk factors. Br J Psychiatry 166:215–228

    Article  PubMed  CAS  Google Scholar 

  • Alvir J, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA (1993) Clozapine-induced agranulocytosis. New England J Med 329:162–167

    Article  CAS  Google Scholar 

  • Aoba A, Kakita Y, Yamaguchi N, Shido M, Tsuneizumi T, Shibata M, Kitani K, Hasegawa K (1985) Absence of age effect on plasma haloperidol neuroleptic levels in psychiatric patients. J Geront 40:303–308

    Article  PubMed  CAS  Google Scholar 

  • Ball CJ (1992) The use of clozapine in older people. Int J Geriatr Psychiatry 7:689–692

    Article  Google Scholar 

  • Ballard CG, Bannister CL, Patel A, Graham C, Oyebode F, Wilcock G, Chung MC (1995) Classification of psychotic symptoms in demented sufferers. Acta Psychiatr Scand 92:63–68

    Article  PubMed  CAS  Google Scholar 

  • Bajulaiye R, Addonizio G (1992) Clozapine in the treatment of psychosis in an 82-year-old woman with tardive dyskinesia. J Clin Psychopharmacol 12:364–365

    PubMed  CAS  Google Scholar 

  • Becker T, Retz W, Hofmann E, Becker G, Teichmann E, Gsell W (1995) Some methodological issues in neuroradiological research in psychiatry. J Neural Transm [Gen Sect] 99:7–54

    Article  CAS  Google Scholar 

  • Bonuccelli U, Ceravolo R, Salvetti S, D’Avino C, Del Dotto P, Rossi G, Murri L (1997) Clozapine in Parkinson’s disease tremor. Effects of acute and chronic administration. Neurology 49:1587–1590

    Article  PubMed  CAS  Google Scholar 

  • Castle DJ, Howard R (1992) What do we know about the aetiology of late-onset schizophrenia? Europ Psychiatry 7:99–108

    Google Scholar 

  • Centorrino F, Baldessarini RJ, Frankenburg FR, Kando J, Volpicelli SA, Flood JG (1996) Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 153:820–822

    PubMed  CAS  Google Scholar 

  • Chacko RC, Hurley RA, Harper RG, Jankovic J, Cardoso F (1995) Clozapine for acute and maintenance treatment of psychosis in Parkinson’s disease. J Neuropsych Clin Neurosci 7:471–475

    CAS  Google Scholar 

  • Cheng YF, Lundberg T, Bondesson U, Lindström L, Gabrielsson J (1988) Clinical pharmacokinetics of clozapine in schizophrenic patients. Eur J Pharmacol 34:445–449

    Article  CAS  Google Scholar 

  • Chengappa KNR, Baker RW, Kreinbrook SB, Adair D (1995) Clozapine use in female geriatric patients with psychoses. J Geriatr Psychiatry Neurol 8:12–15

    PubMed  CAS  Google Scholar 

  • Cohen BM, Sommer BR (1988) Metabolism of thioridazine in the elderly. J Clin Psycho-pharmacol 8:336–339

    CAS  Google Scholar 

  • Cooper A, Kay D, Curry A, Garside RF, Roth M (1974) Hearing loss in the paranoid and affective psychoses of the elderly. Lancet 10:851–854

    Article  Google Scholar 

  • Corbin SL, Eastwood MR (1986) Sensory deficits and mental disorders of old age: causal or coincidental associations? Psychol Med 16:261–256

    Article  Google Scholar 

  • Diederich N, Keipes M, Graas M, Metz H (1995) La clozapine dans le traitement des manifestations psychiatriques de la maladie de Parkinson. Rev Neurol 151:251–257

    PubMed  CAS  Google Scholar 

  • Doraiswamy M, Martin W, Metz A, Deveaugh-Geiss J (1995) Psychosis in Parkinson’s disease: diagnosis and treatment. Prog Neuropsychopharmacol Biol Psychiat 19:835–846

    Article  CAS  Google Scholar 

  • Dose M (1994) Genehmigungspflicht einer Behandlung mit Clozapin nach § 1904 des Betreuungsrechtes? Nervenarzt 65:787–791

    PubMed  CAS  Google Scholar 

  • Durif F, Vidailhet M, Assal F, Roche C, Bonnet AM, Agid Y (1997) Low-dose clozapine improves dyskinesias in Parkinson’s disease. Neurology 48:658–662

    Article  PubMed  CAS  Google Scholar 

  • Eckert A, Reiff J, Müller WE (1998) Arzneimittelinteraktionen mit Antidepressiva. Psycho-pharmakotherapie 5:8–18

    Google Scholar 

  • Factor SA, Brown D (1992) Clozapine prevents recurrence of psychosis in Parkinson’s disease. Mov Disorders 7:125–131

    Article  CAS  Google Scholar 

  • Fischer PA, Baas H, Hefner R (1990) Treatment of parkinsonian tremor with clozapine. J Neural Transm [P-D Sect] 2:233–238

    Article  CAS  Google Scholar 

  • Frankenburg FR, Kalunian D (1994) Clozapine in the elderly. J Geriatr Psychiatry Neurol 7:131–134

    Google Scholar 

  • Friedman JH, Koller WC, Lannon MC, Busenbark K, Swanson-Hyland E, Smith D (1997) Benztropine versus clozapine for the treatment of tremor in Parkinson’s disease. Neurology 48:1077–1081

    Article  PubMed  CAS  Google Scholar 

  • Friedman JH, Lannon MC (1989) Clozapine in the treatment of psychosis in Parkinson’s disease. Neurology 39:1219–1221

    Article  PubMed  CAS  Google Scholar 

  • Friedman JH, Lannon MC (1990) Clozapine-responsive tremor in Parkinson’s disease. Mov Disorders 5:225–229

    Article  CAS  Google Scholar 

  • Greene P, Cote L, Fahn S (1993) Treatment of drug-induced psychosis in Parkinson’s disease with clozapine. Adv Neurology 60:703–706

    CAS  Google Scholar 

  • Gregory C, McKenna P (1994) Pharmacological management of schizophrenia in older patients. Drugs Aging 5:254–262

    Article  PubMed  CAS  Google Scholar 

  • Grief C, Eastwood RM (1993) Paranoid disorders in the elderly. J Geriatr Psychiatry 8:681–684

    Article  Google Scholar 

  • Grimm, R (1987) Leponex® (Clozapine) — Prototyp atypischer Neuroleptika. Wander Pharma, Bern

    Google Scholar 

  • Häfner H, Riecher-Rössler A, Maurer K, Fatkenheuer B, Löffler W, an der Heiden W, Munk-Jørgensen P, Stromgren E (1991) Geschlechtsunterschiede bei schizophrenen Erkrankungen. Fortschr Neurol Psychiat 59:343–360

    Article  PubMed  Google Scholar 

  • Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A (1990) Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 147:1471–1475

    PubMed  CAS  Google Scholar 

  • Herst L, Powell G (1997) Is clozapine safe in the elderly? Aust NZ J Psychiatry 31:411–417

    Article  CAS  Google Scholar 

  • Jerling M, Merlé J, Mentré F, Mallet A (1997) Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol 44:447–453

    Article  PubMed  CAS  Google Scholar 

  • Jeste DV, Eastham JH, Lacro JP, Gierz M, Field MG, Harris MJ (1996) Management of late-life psychosis. J Clin Psychiatry 57 (Suppl. 3):39–45

    PubMed  Google Scholar 

  • Jeste DV, Lacro JP, Gilbert DL, Kline J, Kline N (1993) Treatment of late-life schizophrenia with neuroleptics. Schizophren Bull 19:817–827

    Article  CAS  Google Scholar 

  • Junginger J, Phelan E, Cherry K, Levy J (1993) Prevalence of psychopathology in elderly persons in nursing homes and in the community. Hosp Community Psychiatry 44:381–383

    PubMed  CAS  Google Scholar 

  • Kahn N, Freeman A, Juncos JL, Manning, D, Watts RL (1991) Clozapine is beneficial for psychosis in Parkinson’s disease. Neurology 41:1699–1700

    Article  PubMed  CAS  Google Scholar 

  • Kane JM, Woerner M, Lieberman J (1988) Tardive dyskinesia: Prevalence, incidence and risk factors. J Clin Psychopharm 8:525–565

    Article  Google Scholar 

  • Klimke A, Klieser E (1995) Das atypische Neuroleptikum Clozapin (Leponex®) — aktueller Kenntnisstand und neuere klinische Aspekte. Fortschr Neurol Psychiat 63:173–193

    Article  PubMed  CAS  Google Scholar 

  • Kotrla KJ, Chacko RC, Harper RG, Doody R (1995) Clinical variables associated with psychosis in Alzheimer’s disease. Am J Psychiatry 152:1377–1379

    PubMed  CAS  Google Scholar 

  • Krupp P, Barnes, P (1992) Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry 160 (Suppl. 17):38–40

    Google Scholar 

  • Lew MF, Waters CH (1993) Clozapine treatment of parkinsonism with psychosis. J Am Ger-iatr Soc 41:669–671

    CAS  Google Scholar 

  • Leuchter AF, Spar JE (1985) The late-onset psychoses: clinical and diagnostic features. J Nerv Ment Dis 173:488–494

    Article  PubMed  CAS  Google Scholar 

  • Meltzer HY, Kennedy J, Parsa JDM, Riley D (1995) Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson’s disease. Neuropsychopharmacology 12:39–45

    PubMed  CAS  Google Scholar 

  • Mulsant BH, Gershon S (1993) Neuroleptics in the treatment of psychosis in late life: a rational approach. Int J Geriatr Psychiatry 8:979–992

    Article  Google Scholar 

  • Musser WS, Akil M (1996) Clozapine as a treatment for psychosis in Parkinson’s disease: a review. J Neuropsychiatry Clin Neurosci 8:1–9

    PubMed  CAS  Google Scholar 

  • Myers JK, Weissman MM, Tischler G (1984) Six month prevalence of psychiatric disorders in three communities. Arch Gen Psychiatry 41:959–970

    Article  PubMed  CAS  Google Scholar 

  • Naber D, Leppig M, Grohmann R, Hippius H (1989) Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia — A retrospective study of 387 patients. Psychopharmacology 99 (Suppl):S73–S76

    Article  Google Scholar 

  • Oberholzer AF, Hendriksen C, Monsch AU, Heierli B, Stähelin HB (1992) Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psy-chogeriatrics 4:187–195

    Article  CAS  Google Scholar 

  • Ostergaard K, Dupont E (1988) Clozapine treatment of drug-induced psychotic symptoms in late stages of Parkinson’s disease. Acta Neurol Scand 78:349–350

    Article  PubMed  CAS  Google Scholar 

  • Pakkenberg H, Pakkenberg B (1986) Clozapine in the treatment of tremor. Acta Neurol Scand 73:295–297.

    Article  PubMed  CAS  Google Scholar 

  • Pfeiffer RF, Kang J, Graber B, Hofman R, Wilson J (1990) Clozapine for psychosis in Parkinson’s disease. Mov Disorders 5:239–242

    Article  CAS  Google Scholar 

  • Pinter MM, Helscher RJ (1993) Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson’s disease. J Neural Transm [P-D Sect] 5:135–146

    Article  CAS  Google Scholar 

  • Pirmohamed M, Williams D, Madden S, Templeton E, Park BK (1995) Metabolism and bioactivation of clozapine of human liver in vitro. J Pharmacol Exp Ther 272:984–990

    PubMed  CAS  Google Scholar 

  • Pisciotta AV (1969) Agranulocytosis induced by certain phenothiazine derivates. JAMA 208:1862–1868

    Article  PubMed  CAS  Google Scholar 

  • Pitner JK, Mintzer JE, Pennypacker LC, Jackson CW (1995) Efficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry 56:180–185

    PubMed  CAS  Google Scholar 

  • Platt D (1995) Physiologische Alternsveränderungen und ihre Bedeutung für die Arzneimitteltherapie. Dt Ärztebl 92:A-2258–2261

    Google Scholar 

  • Povlsen UJ, Noring U, Fog R, Gerlach J (1985) Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 71:176–185

    Article  Google Scholar 

  • Retz W, Kornhuber J, Riederer P (1996) Neurotransmission and the ontogeny of human brain. J Neural Transm 103:403–419

    Article  PubMed  CAS  Google Scholar 

  • Retz W, Thome J, Münch G, Rösier M, Kornhuber J (1997 a): Die Transmittersysteme des alternden Gehirns. In: Rösier M, Retz W, Thome J (Hrsg) Alzheimer-Krankheit. Beltz Deutscher Studienverlag, Wiesbaden, S 33–43

    Google Scholar 

  • Retz W, Rösier M, Sitzmann L, Becker T (1997 b) Clozapin in der Behandlung neuropsychia-trischer Erkrankungen im Alter. Fortschr Neurol Psychiat 65:347–353

    Article  PubMed  CAS  Google Scholar 

  • Roberts HE, Dean RC, Stoudemire A (1989) Clozapine treatment of psychosis in Parkinson’s disease. J Neuropsychiatry 1:190–192

    CAS  Google Scholar 

  • Rosenthal SH, Fenton ML, Harnett DS (1992) Clozapine for the treatment of levodopa-in-duced psychosis in Parkinson’s disease. Gen Hosp Psychiatry 14:285–286

    Article  PubMed  CAS  Google Scholar 

  • Ruggieri S, De Pandis MF, Bonamartini A, Vacca L, Stocchi F (1997) Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson’s disease. Clin Neuropharmacology 20:204–209

    Article  CAS  Google Scholar 

  • Safferman AZ, Kane JM, Aronowitz JS, Gordon MF, Pollack S, Lieberman JA (1994) The use of clozapine in neurologic disorders. J Clin Psychiatry 55 (Suppl. B):98–101

    PubMed  Google Scholar 

  • Sajatovic M, Jaskiw G, Konicki PE, Jurjus G, Kwon K, Ramirez LF (1997) Outcome of clozapine therapy for elderly patients with refractory primary psychosis. Int J Geriatr Psychiatry 12:553–558

    Article  PubMed  CAS  Google Scholar 

  • Salzman C, Vaccaro B, Lieff J, Weiner A (1995) Clozapine in older patients with psychosis and behavioral disruption. Am J Geriatr Psychiatry 3:25–33

    Google Scholar 

  • Scholz E, Dichgans J (1985) Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Neurol Sci 235:60–64

    Article  CAS  Google Scholar 

  • Shulman RW, Singh A, Shulman KI (1997) Treatment of elderly institutionalized bipolar patients with clozapine. Psychopharmacol Bull 33:113–118

    PubMed  CAS  Google Scholar 

  • Skoog I, Nilsson L, Landahl S, Steen B (1993) Mental disorders and the use of psychotropic drugs in an 85-year-old urban population. Int Psychogeriatr 5:33–48

    Article  PubMed  CAS  Google Scholar 

  • Smith JM, Baldessarini RJ (1980) Changes in prevalence, severity, and recovery in tardive dyskinesia with age. Arch Gen Psychiatry 37:1368–1373

    Article  PubMed  CAS  Google Scholar 

  • Stephen PJ, Williamson J (1984) Drug induced parkinsonism in the elderly. Lancet 2(8411):1082–1083

    Article  PubMed  CAS  Google Scholar 

  • Stevens I, Mahal A, Gaertner HJ (1995) Clozapinplasmaspiegel bei Akuttherapie von schizophrenen Patienten. Psychopharmakotherapie 2:77–81

    Google Scholar 

  • Swift CG (1990) Pharmacodynamics: changes in homeostatic mechanisms, receptor and target organ sensitivity in the elderly. Br Med Bull 46:36–52

    PubMed  CAS  Google Scholar 

  • Taylor D (1997) Pharmacokinetic interactions involving clozapine. Br J Psychiatry 171:109–112

    Article  PubMed  CAS  Google Scholar 

  • Tegeler J (1992) Clozapin (Leponex®) und Spätdyskinesien. In: Naber D, Müller-Spahn F (Hrsg) Clozapin — Pharmakologie und Klinik eines atypischen Neuroleptikums. Schattauer, Stuttgart, New York, S 71–81

    Google Scholar 

  • Trenkwalder C, Arnold G, Oertel WH (1992) Clozapin (Leponex®) in der Behandlung von Psychosen beim idiopathischen Parkinson-Syndrom. In: Naber D, Müller-Spahn F (Hrsg) Clozapin — Pharmakologie und Klinik eines atypischen Neuroleptikums. Schattauer, Stuttgart, New York, S 89–97

    Google Scholar 

  • Varner RV, Gaitz CM (1982) Schizophrenia and paranoid disorders in the aged. Psychiatr Clin North Am 5:107–118

    PubMed  CAS  Google Scholar 

  • Verghese C, Kessel JB, Simpson GM (1991) Pharmacokinetics of neuroleptics. Psychopharm-col Bull 27:551–563

    CAS  Google Scholar 

  • Wagner ML, Defilippi JL, Menza MA, Sage JI (1996) Clozapine for the treatment of psychosis in Parkinson’s disease: chart review of 49 patients. J Neuropsychiatry 8:276–280

    CAS  Google Scholar 

  • Weiler M, Kornhuber J (1993) Clozapin: Risikoneuroleptikum für die Auslösung eines malignen neuroleptischen Syndroms (MNS) oder neuroleptische Alternative bei positiver MNS-Anamnese? Fortschr Neurol Psychiat 61:217–222

    Article  Google Scholar 

  • Wölk SI, Douglas CJ (1992) Clozapine treatment of psychosis in Parkinson’s disease: a report of five consecutive cases. J Clin Psychiatry 53:373–376

    PubMed  Google Scholar 

  • Wolters EC, Hurwitz TA, Mak E, Teal P, Peppard FR, Remick R, Calne S, Calne DB (1990) Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 40:832–834

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. W. Retz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Rösler
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische und Nervenklinik, Univ.-Krankenhaus Eppendorf, Martinistraße 52, D-20246, Hamburg, Deutschland

    D. Naber

  2. Psychiatrische Universitätsklinik, Wilhelm-Klein-Straße 27, CH-4025, Basel, Switzerland

    F. Müller-Spahn

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Retz, W., Rösler, M. (1999). Behandlung älterer Patienten mit Clozapin. In: Naber, D., Müller-Spahn, F. (eds) Leponex. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-08362-8_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-08362-8_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-64707-2

  • Online ISBN: 978-3-662-08362-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation